



DISA Limited  
(Company Registration No. 197501110N)  
(Incorporated in the Republic of Singapore)  
("Company" and together with its subsidiaries, the "Group")

---

**APPOINTMENT OF DIRECTOR AND CHANGE IN SHAREHOLDINGS AT DIGITAL LIFE LINE PTE. LTD., A SUBSIDIARY OF DISA DIGITAL SAFETY PTE. LTD.**

---

Further to the announcement pertaining to the appointment of directors and change in shareholdings at Digital Life Line Pte. Ltd. ("DLL") dated 29 December 2021, the board of directors (the "Board") of the Company wishes to announce the following:

**(1) Dr. Chua Lee Kiang, Melvin will be appointed as the director of DLL with effect from 12 January 2022**

Dr. Melvin Chua, who is also one of the inventors of the new saliva-based COVID-19 ART technology, is a Clinician-Scientist at the National Cancer Centre Singapore, and Principal Investigator of the Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Beam Therapy – Precision Radiation Oncology Programme. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology and the Director of the Data and computational Science Core. His research is supported by the NMRC (National Medical Research Council) Clinician-scientist award, and is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharyngeal (NPC) and prostate cancers.

He graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-doctoral Clinician-scientist fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Center, Toronto. In 2021, he obtained his fellowship of the Academy of Medicine Singapore under the College of Radiation Oncology and Clinician Scientists.

Dr. Chua is a KOL (Key Opinion Leader) on NPC (Nasopharyngeal Carcinoma) and prostate cancer, and he has been invited to speak at more than 100 international meetings. He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network, a board member on the Head Neck Cancer International Group (HNCIG) and the Scientific Committee Chairman of HNCIG Artificial Intelligence working group.

Following the abovementioned appointment, with effect from 12 January 2022, the composition of the Board of DLL shall be as follows:

Professor Soo Khee Chee, Chairman  
Dr. Chua Lee Kiang, Melvin  
Dr. Guy Heathers  
Mr. John Wong Weng Foo  
Mr. Chng Weng Wah, Managing Director and CEO  
Mr. Han Yang Kwang

## (2) Change in Shareholding Percentage of DLL

The Board wishes to announce that Disa Digital Safety Pte. Ltd. (“**DiSa**”), a wholly owned subsidiary of the Company, has transferred 21,000 shares, representing 42% of the total issued and paid-up capital of DLL, to DLL Directors, Dr. Chua Lee Kiang, Melvin, Dr. Guy Heathers and Blade Research Pte. Ltd., a private limited company wholly-owned by Professor Soo Khee Chee:

Transferee	No. of Shares Transferred	Subscription Price	Shareholding (%)
Blade Research Pte. Ltd.	18,500	S\$1,850.00	37%
Dr. Chua Lee Kiang, Melvin	2,000	S\$200.00	4%
Dr. Guy Heathers	500	S\$50.00	1%

Following the above transfer, with effect from 12 January 2022, the composition of shareholders of DLL shall be as follows:

Name of Shareholder	No. of Shares Held	Shareholding (%)
DiSa	20,000	40%
Blade Research Pte. Ltd.	18,500	37%
Chng Weng Wah *	3,500	7%
Professor Soo Khee Chee	3,000	6%
John Wong Weng Foo	2,500	5%
Dr. Chua Lee Kiang, Melvin	2,000	4%
Dr. Guy Heathers	500	1%
Total	50,000	100%

\* Chng Weng Wah is the Managing Director and Chief Executive Officer and substantial shareholder of the Company.

The above transfer is considered a non-discloseable transaction under Rule 1008 of the Catalyst Rules.

### BY ORDER OF THE BOARD

Chng Weng Wah  
Managing Director and Chief Executive Officer  
12 January 2022

*This announcement has been reviewed by the Company’s sponsor, SAC Capital Private Limited (“**Sponsor**”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Ong Hwee Li (Registered Professional, SAC Capital Private Limited)*

*Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.*

*Telephone number: +65 6232 3210*

### About Digital Life Line Pte. Ltd.

DLL, a 42% owned company of Disa Digital Safety Pte. Ltd., is a Singapore-based company that deals with the manufacturing and distribution of saliva-based Antigen Rapid Test (ART) kits. Digital Life Line has signed tri-party licensing agreement with National University of Singapore (“**NUS**”) and Singapore Health Services Pte. Ltd. (“**SingHealth**”) on 8 December 2021 for the use of their new saliva-based COVID-19 ART technology. This technology was co-developed by SingHealth Duke-NUS Academic Medical Centre and the NUS.

### **About DiSa Digital Safety Pte. Ltd.**

DiSa, a wholly-owned subsidiary of DISA Limited, is a Singapore-based technology solution provider that specializes in research and development of cutting-edge digital security solution (“**DiSa Asset Protection System**”). With its single scan technology and seamless integration, DiSa has been able to provide item level tracking and data with no disruption to the sales process. This technology is now protecting products and categories previously unachievable with traditional serialization methods, saving millions of dollars in prevented returns.

DiSa entered the US market in 2014 launching its Smart Solutions within the largest retailer in the world with a limited store test. After rigorous testing by the Loss Prevention Research Council, USA, DiSa rolled out its Smart Solutions nationwide in 2017.

### **About DISA Limited**

DISA Limited (SGX: 532), is a publicly-traded company on the Singapore Catalist Stock Exchange. More information is available at <http://www.digital-safety.com>.